Elon Musk’s Neuralink will likely collect sizeable revenue from its N1 brain implant in out years, according to an analyst at Ark Investment Management.
If the N1 module and R1 surgical robot succeed in getting FDA approval for ALS, a neurodegenerative disorder that results in progressive degeneration of nerve cells in the spinal cord and brain, and cervical spinal cord injuries, there will likely be modest adoption by 2025, said Ark analyst Pierce Jamieson.
